Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Ocata Therapeutics, Inc. | actc_ex9901.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 14, 2014
ADVANCED
CELL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-50295 | 87-0656515 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 33 Locke Drive, Marlborough, Massachusetts | 01752 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant's Telephone Number, Including Area Code: (508) 756-1212
_____________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On October 14, 2014, Advanced Cell Technology, Inc. (the “Company”) issued a press release announcing the October 14,
2014 publication online by The Lancet, of results from a Company-sponsored Phase 1/2 clinical trial regarding the
safety and tolerability of sub-retinal transplantation of human embryonic stem cell-derived retinal pigment epithelial cells transplanted
into patients with Stargardt’s macular dystrophy and dry age-related macular degeneration.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
Item 9.01 Financial Statement and Exhibits.
Exhibit Number Description
| Exhibit Number |
Description | |
| 99.1 | Press Release Dated October 14, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Advanced Cell Technology, Inc. | ||
| Date: October 15, 2014 | By: | /s/ Edward Myles |
| Edward Myles Chief Operating Officer & Chief Financial Officer | ||
EXHIBIT INDEX
|
Exhibit |
Description | |
| 99.1 | Press Release, dated as of October 14, 2014 | |